Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 g/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), ␤-thromboglobulin (␤-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1+2 (F1+2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 ؎ 0.32 U/ml to 1.83 ؎ 0.69 U/ml; P Ͻ 0.001), in vWF activity (from 1.04 ؎ 0.34 U/ml to 1.78 ؎ 0.50 U/ml; P Ͻ 0.001) and in FVIII:C (from 1.12 ؎ 0.37 U/ml to 1.73 ؎ 0.57 U/ml; P Ͻ 0.001) after G-CSF. Of note, four donors with low baseline vWF had a two-to three-fold increase after receiving G-CSF. G-CSF had no impact on the platelet count, ␤-TG, PF-4, GMP-140 or PAC-1. The final% of platelet aggregation decreased from 73 ؎ 22% to 37 ؎ 26% after G-CSF (P Ͻ 0.001). We found a significant decrease in aPTT after G-CSF (29.9 ؎ 3.1 s to 28.3 ؎ 3.3 s; P = 0.004), but the PT was unaffected. In addition, we also observed a significant increase in TAT, F1+2 and TM, but not in tPA:Ag. Our data suggest that G-CSF may possibly induce a hypercoagulable state by increasing levels of FVIII:C and thrombin generation. In contrast to this information, we found reduced platelet aggregation after G-CSF administration. The clinical implications of these findings remain unclear and larger studies are definitely required.
The last few years have witnessed an important increase in the use of peripheral blood stem cells (PBSC) for allogeneic transplantation. Granulocyte colony-stimulating factor (G-CSF) is currently the most widely used cytokine for stem cell mobilization. Exposing a large number of otherwise healthy individuals to G-CSF raises concerns about potential adverse effects. 1 Although usually well tolerated, G-CSF administration commonly induces side-effects such as bone pain, headaches, fatigue and nausea. Anxiety, noncardiac chest pain, myalgia, insomnia, fever, night sweats, skin rash, anorexia, dizziness, weight gain, local reactions at the injection site and vomiting have been infrequently reported. G-CSF has been extensively used for the treatment of neutropenia following chemotherapy, but short-and long-term side-effects of G-CSF in normal individuals are not well defined.
In a few small studies, G-CSF was found to induce platelet activation. Shimoda and others have shown that G-CSF receptors are present on the surface of platelets. 2, 3 These receptors appear to be functional in vitro 2 and in vivo 4, 5 in healthy volunteers. However, the consequences on hemostasis of these findings are conflicting. Other investigators have also observed an increase in platelet aggregation, in platelet activation, in von Willebrand factor and in thrombin-antithrombin complex after G-CSF, but these results could not be confirmed. 2, [4] [5] [6] [7] [8] [9] [10] To date, two cases of thrombosis occurring in normal donors have been reported. 11 The first one was a healthy 54-year-old woman who developed a cerebrovascular accident 2 days after completing an uneventful stem cell donation. The second one was a 64-year-old man with a history of coronary artery disease who experienced a myocardial infarction shortly after PBSC collection.
These clinical and biological observations raise concerns about the possibility that G-CSF might in fact induce a hypercoagulable state in healthy donors and consequently, increase the risk of thrombosis. In order to better define the effects of G-CSF on hemostasis, we undertook a prospective study in healthy PBSC donors focusing on short-term adverse effects and on hemostatic changes immediately after G-CSF administration.
Materials and methods

Study design
This is a cohort study, conducted at St Sacrement Hospital, Laval University, Quebec City, Canada. It was approved by the institutional review board and written consent was obtained from all healthy donors prior to participation.
Patients
Between July 1996 and April 1998, all consecutive healthy allogeneic PBSC donors were considered for enrollment in the study. All donors studied were used as their own control. Donors were excluded if they had an abnormal platelet count, bleeding time, activated partial thromboplastin time (aPTT) or prothrombin time (PT) prior to G-CSF. Other exclusion criteria were a history of unstable angina, myocardial infarction, ischemic or thrombotic stroke in the past 3 months, active neoplasia, active inflammatory disease, pregnancy or a contra-indication to blood donation.
Intervention
All donors were evaluated initially by a physician and a nurse with a complete medical history and physical examination. At their first visit, they were instructed on how to administer their medication and on the potential sideeffects. Before the first dose of G-CSF, blood samples were drawn for laboratory evaluation. All donors received G-CSF (Neupogen, Amgen, Mississauga, Canada) at 5 g/kg subcutaneously twice daily for nine consecutive doses. After the ninth dose on day 5, blood samples were drawn for the same assays immediately before undergoing leukapheresis. A personal diary was provided to all donors in order to record prospectively any side-effects experienced during the period of G-CSF administration. Side-effects were graded by one investigator after discussion with the donor on a scale of 1 to 4; grade 1 were mild side-effects with no intervention needed; grade 2 were moderate sideeffects needing some intervention (acetaminophen to relieve bone pain or fever) but not interfering with drug administration; grade 3 were severe side-effects interfering with normal daily activity or with the need to discontinue medication; grade 4 were life-threatening complications related to the medication. In order to attribute symptoms only to G-CSF administration, all donors were instructed to start recording symptoms in their diary 5 days prior to G-CSF administration.
Laboratory testing
Blood collection: Thirty-five to 40 ml of blood were collected from each donor before G-CSF and after 96 h, immediately before leukapheresis. EDTA anticoagulated blood was used for platelet count and to look for specific markers expressed on activated platelets: (1) anti-P-selectin against alpha-granule membrane glycoprotein (GMP-140) and (2) anti-glycoprotein (gp) against the activated configuration of gp IIb-IIIa complex (PAC-1). Cooled Diatube H CTAD containing a mixture of citrate, theophylline, adenosine and dipyridamole (Becton Dickinson, Meylan, France) was used to collect blood for ␤-thromboglobulin (␤-TG) and platelet factor 4 (PF-4) assays according to the Diagnostica Stago protocol: after 30 min in an ice/water bath, blood was centrifuged at 13 000 g for 30 min at 4°C and the plasma was stored at Ϫ80°C until used. aPTT, PT, coagulant factor VIII (FVIII:C), von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), thrombinantithrombin complex (TAT), prothrombin fragment 1+2 (F1+2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) assays were performed on plasma obtained from anticoagulated blood with citrate (Becton Dickinson, 0.105 mol/l) and centrifuged at 2500 g for 15 min at 4°C. Plasma samples were analyzed immediately or stored in aliquots at Ϫ80°C until tested. For assaying, samples were thawed for 15 min in a 37°C water-bath. The Monovette blood collection system (Sarstedt, NC, USA) containing sodium citrate (0.105 mol/l) was used for platelet aggregation. Platelet-rich plasma was obtained by centrifugation at 250 g for 6 min at 27°C and was adjusted with platelet-poor plasma (2500 g for 15 min at 27°C) to a platelet count of 200 × 10 9 /l. . PT and aPTT were carried out on the Behring Fibrintimer A (BFA, Behringwerke, Marburg, Germany) using Thromborel-S (Behring) and Automated APTT (Organon Teknika) respectively. FVIII:C was measured by one stage clotting assay on the BFA instrument using immunoadsorbed FVIII deficient plasma (Dade, Miami, FL, USA). vWF:Ag, ␤-TG, PF-4, TM and tPA:Ag were performed by enzyme-linked immunosorbent assays (ELISA) using Asserachrom kits (Diagnostica Stago, Asnières-surSeine, France). vWF activity was determined using IMUB-IND vWF ELISA kit (American Diagnostica, Greenwich, CT, USA). Enzygnost ELISA kits (Behringwerke) were used for TAT and F1+2 determinations. ELISA assays were all carried out on CODA Automated EIA Analyzer (BioRad, Hercules, CA, USA). Normal pooled plasma (NPP) was used for calibration with a defined value of 1 U/ml. Normal values for each test were established on 50 normal subjects and were defined as the mean Ϯ 2 standard deviations (s.d.). The following tests were not performed in the donors who were taking antiplatelet agents (acetylsalicylic acid, ticlopidine, nonsteroidal anti-inflammatory drugs) at the time of enrollment: platelet aggregation tests and the assays for ␤-TG, PF-4, GMP-140 and PAC-1.
Statistical analysis
Mean levels Ϯ 1 s.d. were calculated for platelet count, vWF:Ag, vWF activity, ␤-TG, PF-4, GMP-140, PAC-1, PT, aPTT, VIIIc, percentage of final and maximal platelet aggregation, TAT, F1+2, TM, tPA:Ag before and after G-CSF administration. Those values were compared using the Student's paired t-test.
Results
Patients
Twenty-four consecutive healthy individuals were evaluated during the study period. Two donors were excluded (one because of inadequate blood samples and the other had active rheumatoid arthritis), leaving 22 donors for evaluation. There were 10 females and 12 males, aged from 20 to 63 years (mean 40). Of these 22 donors, two were on ASA at the initial visit and were subsequently excluded from the analysis of the platelet functional assays.
Adverse effects
Side-effects experienced by donors while on G-CSF are shown in Table 1 . G-CSF was well tolerated by all donors. Graded side-effects were low in intensity (grade 2/4 or less): bone pain was present in 82% of the donors, mainly in the pelvis, and totally or partially relieved by acetaminophen; fatigue and malaise in 64%; headache in 55%; myalgia in 41%. Less frequently reported symptoms included fever (27%), nausea (18%), cough (14%) and dyspnea (9%). However, some complaints were also present in donors before G-CSF administration, at the same intensity (dyspnea in 9%, fatigue and malaise, myalgia and cough in 5%) ( Table 1) . No donor had to discontinue G-CSF administration due to side-effects. No bleeding or thrombotic events were reported during or after G-CSF.
Effect of G-CSF on hemostasis
All donors had a normal platelet count, as well as bleeding time, PT and aPTT prior to G-CSF. As shown in Table 2 and Figure 1 , a significant rise in the level of vWF:Ag, vWF activity and FVIII:C was observed: vWF:Ag increased from 0.99 Ϯ 0.32 U/ml to 1.83 Ϯ 0.69 U/ml (P Ͻ 0.001), vWF activity from 1.04 Ϯ 0.34 U/ml to 1.78 Ϯ 0.50 U/ml (P Ͻ 0.001), and FVIII:C from 1.12 Ϯ 0.37 U/ml to 1.73 Ϯ 0.57 U/ml (P Ͻ 0.001). Four donors presented low baseline values (Ͻ 0.7 U/ml) of vWF:Ag and vWF activity prior to G-CSF, but none had a bleeding history. G-CSF induced a two-to three-fold increase in all four of them: vWF:Ag increased from 0.49 Ϯ 0.11 to 1.11 Ϯ 0.31 U/ml (P = 0.012) and vWF activity from 0.48 Ϯ 0.11 to 1.08 Ϯ 0.29 U/ml (P = 0.011). Even after exclusion of the results obtained from these four donors, the difference for vWF:Ag and vWF activity, prior and after G-CSF, remains significant. Of importance, vWF:Ag and vWF activity were higher in all donors after G-CSF. The aPTT was significantly shortened from 29.9 Ϯ 3.1 s prior to 28.3 Ϯ 3.3 s after G-CSF (P = 0.004). We observed a significant rise in the levels of TAT, F1+2 and TM after G-CSF with mean levels before and after of 2.30 Ϯ 0.57 to 4.48 Ϯ 4.28 g/l (P = 0.022), 0.76 Ϯ 0.24 to 1.52 Ϯ 0.61 nmol/l (P Ͻ 0.001) and 26.7 Ϯ 11.3 to 60.8 Ϯ 17.9 ng/ml (P Ͻ 0.001), respectively. We found no effects of G-CSF on the PT and the tPA:Ag levels ( Table  2) .
In order to document the effects of G-CSF on platelet function, we studied the platelet count, ␤-TG, PF-4 and two surface markers of platelet activation: GM-140 and PAC-1. None of these variables were significantly different after G-CSF. In contrast, we observed a significant decrease in the final percentage of ADP-induced platelet aggregation after 8 min using ADP at a concentration of 3 m: aggregation decreased from 73 Ϯ 22% to 37 Ϯ 26% following G-CSF (P Ͻ 0.001) ( Table 2 and Figure 1 ). Similar results were observed using the maximal % of platelet aggregation (decrease from 78 Ϯ 17% to 50 Ϯ 16%; P Ͻ 0.001).
Discussion
G-CSF is widely used for PBSC mobilization in allogeneic transplantation. Increasing numbers of otherwise asymptomatic donors are being exposed to a short course of G-CSF. Recent findings of G-CSF receptors on the surface of platelets 2,3 and a few reported cases of acute arterial thrombosis in patients receiving G-CSF support the hypothesis that a transient hypercoagulable state may be induced by G-CSF. In 1992, Conti et al 12 reported the first case of acute thrombosis in the left popliteal artery of a 69-yearold man without risk of cardiovascular disease, receiving G-CSF following chemotherapy for bladder carcinoma. The authors assumed that hyperleukocytosis (leukocyte count of 70.5 × 10 9 /l) induced by G-CSF, with a presumably subsequent hypercoagulable state, was a contributing factor for the occurrence of thrombosis. In 1996, Kawachi et al 13 reported the case of a 44-year-old man with a non-Hodgkin's lymphoma, who presented with an acute thrombosis in the distal aorta. He was receiving G-CSF for chemotherapy-induced neutropenia and had no predisposing cardiovascular factors. After the patient was re-challenged with rhG-CSF, an increase in ADP-and collagen-induced platelet aggregation was demonstrated. The authors postulated that both a rapid increase in the patient's platelet count and a direct aggregating effect of G-CSF were responsible for thrombosis. In addition, other cases of arterial thrombosis or other vascular complications have been reported in patients who were also receiving chemotherapy concurrently with G-CSF. 14 To date, only two case reports of acute arterial thrombosis occurring in healthy donors that might be related to G-CSF have been published. 11 In this study, G-CSF was well tolerated with no significant adverse reaction. We found that G-CSF at 5 g/kg twice daily for nine doses induces a significant increase in Table 2 Hemostatic parameters before and after G-CSF administration in healthy donors vWF:Ag which correlates with vWF activity. vWF is both secreted by the platelet ␣-granules and the endothelial Weibel-Palade bodies. Our findings do not support a rise in vWF derived from platelet secretion, because it is not associated with a concomitant increase in plasma ␤-TG, PF-4, GMP-140 and PAC-1. In contrast, the rise in TM, which is secreted by endothelial cells, may suggest an endothelial origin for vWF. However, we have not observed a concomitant rise in tPA:Ag which is also derived from endothelial cells. It is possible that because of its very short half-life, the plasma level of tPA:Ag is too temporary to be representative of endothelial secretion. At the present time, the exact origin and mechanism responsible for the increase in vWF remains unexplained. It is possible that the rise in vWF may be unrelated to G-CSF administration, but result from psychological or emotional stresses associated with the procedure. Hemostatic changes have been documented following acute mental stress with a significant rise in vWF level. 15 PBSC donation to a family member is clearly a stressful situation for many individuals but, in our opinion, the constant and significant rise in the level of vWF observed in our study argues in favor of a direct role for G-CSF. However, no matter how the increase in the level of vWF observed in our study is produced, a review of patients receiving desmopressin as a hemostatic drug during surgery demonstrate that it does not increase the incidence of thrombosis despite a significant rise in the level of vWF associated with its administration. 16, 17 Therefore, the rise in vWF, by itself, is not sufficient to explain a predisposition to thrombosis.
In our study, we also demonstrate a statistically significant rise in FVIII:C, TAT and F1+2 after G-CSF. In one study, FVIII:C levels exceeding 1.5 U/ml were associated with a six-fold increase in the risk of thrombotic events as compared to levels below 1.0 U/ml.
18 F1+2 and TAT are markers of thrombin generation and have been extensively evaluated in patients with hypercoagulable state. Several patients with hereditary deficiencies such as antithrombin III and protein C have higher levels of F1+2 than normal individuals. 19, 20 In addition, oral anticoagulants suppress thrombin generation with a significant reduction in F1+2. 21, 22 Although it has been suggested that among patients with a hypercoagulable state, higher levels of F1+2 could identify a subgroup of patients with higher risk of thrombosis, this observation remains to be proven. Therefore, although we documented an increase in F1+2 and TAT levels in patients receiving G-CSF, the clinical significance of this finding remains unclear.
Our finding of a decrease in platelet aggregation after G-CSF is surprising considering that previous studies have reported either no significant change or an increase in platelet aggregation, and that the clinical events reported were arterial thrombosis. However, the timing of testing might be important since it has been demonstrated that platelet aggregation increases when tested soon after G-CSF (within 18 h), [3] [4] [5] [6] while no change is seen when it is tested at 48 and 96 h. 7 In our study, platelet aggregation was tested slightly more than 96 h after G-CSF, and we demonstrate a decrease in platelet aggregation that was very consistent in all patients but one. A phenomenon of 'platelet exhaustion' was reported after strenuous exercise of long duration, 23 during hemolytic-uremic syndrome, 24 and during pre-eclampsia. 25 Whether this occurs in our patients also remains unclear.
In summary, we found that normal individuals receiving G-CSF to mobilize hematopoietic stem cells have an increase in vWF, FVIII:C and evidence of thrombin generation. Although this may indicate that G-CSF induces an hypercoagulable state, the correlation with clinical thrombosis has yet to be proven. Large numbers of healthy donors exposed to G-CSF will need to be evaluated in order to determine the risk of thrombosis in this population, and we encourage all cases of thrombosis in healthy donors to be reported. Meanwhile, there has been a suggestion that since most events reported were arterial, anti-platelet agents should be considered in healthy donors with symptomatic or severe atherosclerosis or past history of thrombosis. 6 Our study has not demonstrated any clear evidence of platelet aggregation or activation and therefore does not support a role for these agents, especially regarding our findings on platelet aggregation. Heparin or other anticoagulants could be of benefit in view of our demonstration of thrombin generation after G-CSF, but we cannot make a recommendation only on the basis of these results. More studies will be needed to answer these questions.
